I The activity and pulmonary metabolism of two peptides, 7-homo Pro-bradykinin and 8-homo Phebradykinin were studied in isolated systems. 2 Both analogues were about 50-70 times less active than bradykinin on the guinea-pig ileum and 70-160 times less active on isolated strips of cat terminal ileum. 3 The action of both analogues on guinea-pig ileum was potentiated (2.5-3.0 fold) by a bradykinin potentiating peptide (BPP9a) but less so than the action of bradykinin (4-5 fold).
Introduction
Bradykinin is extensively inactivated during passage through the pulmonary circulation by the action of peptidases. The original findings in vivo (Ferreira & Vane, 1967) were extended using isolated lungs of various species. For example, in rat isolated lungs, bradykinin perfused through the pulmonary circulation suffers hydrolysis at several bonds ( Figure 1 ; Ryan, Roblero & Stewart, 1970) . Since the hydrolysis of any peptide bond of bradykinin leads to its virtual inactivation (Suzuki, Abiko, Endo, Kameyama, Sasaki & Nabeshima, 1969) , any one of the cleavages shown in Figure 1 could represent the action of the fastest acting peptidase and all the other cleavages due to other peptidases would be relatively unimportant in terms of the pulmonary inactivation. One of the pulmonary bradykininases, angiotensin converting enzyme (dipeptidylcarboxypeptidase, E. C.
3. 4. 15. 1) has been well characterized (Soffer, 1976) but its importance relative to the other pulmonary bradykininases has not been assessed. Since two recently synthesized analogues, 7-homo Pro- bradykinin and 8-homo Phe-bradykinin, were said to be resistant to hydrolysis by converting enzyme (Ondetti & Engel, 1975) , it was decided to investigate their metabolism relative to that of bradykinin in isolated lungs.
Methods
Isolated lungs of rats and guinea-pigs of either sex were perfused via the pulmonary artery with oxygenated Krebs solution at 37°C as described earlier (Bakhle, Reynard & Vane, 1969 
Activity ofbradykinin analogues on isolated tissues
The first experiments were designed to assess the potency of the analogues relative to the parent peptide on the two isolated smooth muscle preparations that were to be used later to study the pulmonary metabolism of the peptides. 7-Homo Pro-bradykinin, 8-homo Phe-bradykinin, and bradykinin were assayed on the same preparations, guinea-pig ileum and cat terminal ileum (Figure 2 ). The potency of the analogues was expressed as bradykinin equivalents (Table 1) . On the cat terminal ileum the ,B-homo analogues had different potencies whereas on the guinea-pig ileum they were effectively equipotent.
The responses of the guinea-pig ileum to bradykinin are potentiated by the nonapeptide, BPP9a (Ferreira, Greene, Alabaster, Bakhle & Vane, 1970) . The effects of a constant infusion of BPP9a on the responses of the guinea-pig ileum to bradykinin and the two analogues are shown in Table 2 . The fi-homo analogues were potentiated to a lesser degree than bradykinin. The responses of the cat terminal ileum to the fi-homo analogues, like those to bradykinin (Alabaster & Bakhle, 1972) , were not potentiated by BPP9a.
Inactivation in isolated lungs
Like bradykinin, both fi-homo analogues were inactivated on a single passage through guinea-pig and rat isolated lungs, though there were important quantitative differences. The relationship between the amount of f-homo analogue injected into the pulmonary artery and the amount of activity surviving passage through the pulmonary circulation of guineapig and rat lungs is shown in Figure 3 . In both species, 7-homo Pro-bradykinin showed a higher survival than 8-homo Phe-bradykinin. Furthermore, although the 8-homo Phe analogue, like bradykinin itself, was over 90% inactivated in both guinea-pig and rat lungs, over 40% of the 7-homo Pro analogue survived in guineapig lungs, more than 4 times its survival in rat lungs.
The bradykinin potentiating peptide, BPP9a, is also a specific inhibitor of the dipeptidylcarboxypeptidase that hydrolyses angiotensin I and bradykinin. Figure 4 shows that in guinea-pig lung, an infusion of BPP9a (100 ng/ml) increased survival of bradykinin and 8-homo Phe-bradykinin five-fold (P<0.05), whereas the already high survival of 7-homo Pro-bradykinin was not affected. At the higher concentration of BPPga (500 ng/ml) there was a small further increase in survival of bradykinin and its 8-homo Phe analogue and a non-significant change in the survival of 7-homo Pro-bradykinin. In rat lung, survival of all three peptides is much lower than in guinea-pig lung but BPP9a again increased survival of bradykinin and 8-homo Phe-bradykinin (P <0.05), whereas survival of the 7-homo Pro analogue was not significantly changed even at the higher concentration of BPP9a
(500 ng/ml).
Discussion
The (Ferreira, 1965) , but subsequently a direct interaction of the potentiator with the receptor has been postulated (Camargo & Ferreira, 1971) . If this is so, then the changes in the receptor brought about by BPP9a are not as effective for the analogues as they are for bradykinin. Furthermore, although the analogues are equally active on the guinea-pig ileum, the 8-homo Phe analogue was more potentiated by BPP9a than the 7-homo Pro analogue. The analogues were both designed to be resistant to the major bradykinin hydrolysing enzyme in lung, the dipeptidylcarboxypeptidase or angiotensin converting enzyme. This enzyme (see Figure 1 ) is known to cleave bradykinin initially at the Pro7-Phe8 bond (Dorer, Kahn, Lentz, Levine & Skeggs, 1974) and therefore substitutions at Pro7 or Phe8 were expected to interfere with the action of the enzyme.
Furthermore, BPP9a which protects bradykinin from inactivation by dipeptidylcarboxypeptidase should have no effect on the inactivation, if any, of the analogues. Even under conditions of maximal inhibition of converting enzyme, some inactivation of the analogues would be expected, as the other bradykinin hydrolysing peptidases (see Figure 1) would not be inhibited.
The expected resistance to dipeptidylcarboxypeptidase was found only with 7-homo Pro-bradykinin. This analogue was more resistant than bradykinin to inactivation in the isolated lung and the inactivation that did occur was unaffected by concentrations of BPP9a that gave near mL ;mal protection to bradykinin. 8-Homo Phe-bradyk. * was, like bradykinin, rapidly inactivated by the lunb, and protected by BPP9a. These results lead to the conclusion that 7-homo Pro-bradykinin was not a substrate or at best a very poor substrate, for converting enzyme, whereas 8-homo Phe-bradykinin was a substrate.
These conclusions are at variance with those of Ondetti & Engel (1975) . They found that a purified converting enzyme preparation from rabbit lung liberated the C-terminal dipeptide Phe-Arg from bradykinin, but not from the two analogues and concluded that neither analogue was a substrate for converting enzyme. However, the results of their experiments in vivo were not compatible with this conclusion, as 8-homo Phe-bradykinin was a less potent vasodepressor than bradykinin and its effects, like those of bradykinin, were enhanced by a previous Table 2 Potentiation by BPP9a of the contractor effects of bradykinin and two analogues on guinea-pig The BPPga in a final concentration of 100 ng/ml was superfused continuously over the isolated tissues for at least 15 min before, and during the administration of the agonist peptides. t Dose equivalent is the amount of agonist that would be required to give an equivalent contraction on untreated tissue; thus 1 ng of bradykinin causes a contraction of treated ileum equivalent to that given by 5 ng of bradykinin on the ileum before treatment (mean ± s.e. mean). Number of experiments is given in parentheses. These differences between the properties of the analogues in vivo agree well with the findings that 8-homo Phe-bradykinin, but not 7-homo Pro-bradykinin, was a substrate for converting enzyme. My findings also suggest that, in vivo, relatively more 7-homo Pro-bradykinin survives the pulmonary, blood and peripheral converting enzymes and is recirculated. This would explain the longer hypotension (2.1 min) produced by 7-homo Pro-bradykinin, compared with bradykinin or 8-homo Phe-bradykinin (0.5-0.4 min) (Ondetti & Engel, 1975) .
The present study also provides information on the level of angiotensin converting enzyme activity in isolated lungs. The inactivation of 7-homo Pro-bradykinin can be taken as an indication of the proportion of converting enzyme relative to the other bradykinin hydrolysing peptidases; thus in guinea-pig lung about half, and in rat, nearly all of the total bradykinin hydrolysing activity was due to peptidases other than converting enzyme. These results also suggest that these other peptidases inactivate bradykinin and the two analogues at very similar rates, possibly because these enzymes are acting at bonds not involving the Pro7 or Phe8 residues (see Figure 1 ). This indirect estimate of a low level of converting enzyme activity in rat isolated lungs agrees with the direct estimation of the conversion of angiotensin I to angiotensin II in isolated lungs (Bakhle, Reynard & Vane, 1969) and with results obtained in vivo (Kreye & Gross, 1971) suggesting that in the rat, conversion of angiotensin I in the lung is less than in the peripheral circulation. This large difference (four-fold) in converting enzyme activity in the lungs of two common laboratory animals means that results obtained in one species cannot be compared directly with those obtained in the other species.
